Related Experiment Video
Updated: Feb 13, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Profiling Prostate Cancer Therapeutic Resistance
Cameron A Wade1, Natasha Kyprianou2,3,4
1Departments of Urology, University of Kentucky College of Medicine, Lexington, Kentucky, KY 40536, USA. cameron.wade@uky.edu.
Abstract:
The major challenge in the treatment of patients with advanced lethal prostate cancer is therapeutic resistance to androgen-deprivation therapy (ADT) and chemotherapy. Overriding this resistance requires understanding of the driving mechanisms of the tumor microenvironment, not just the androgen receptor (AR)-signaling cascade, that facilitate therapeutic resistance in order to identify new drug targets. The tumor microenvironment enables key signaling pathways promoting cancer cell survival and invasion via resistance to anoikis. In particular, the process of epithelial-mesenchymal-transition (EMT), directed by transforming growth factor-β (TGF-β), confers stem cell properties and acquisition of a migratory and invasive phenotype via resistance to anoikis. Our lead agent DZ-50 may have a potentially high efficacy in advanced metastatic castration resistant prostate cancer (mCRPC) by eliciting an anoikis-driven therapeutic response. The plasticity of differentiated prostate tumor gland epithelium allows cells to de-differentiate into mesenchymal cells via EMT and re-differentiate via reversal to mesenchymal epithelial transition (MET) during tumor progression. A characteristic feature of EMT landscape is loss of E-cadherin, causing adherens junction breakdown, which circumvents anoikis, promoting metastasis and chemoresistance. The targetable interactions between androgens/AR and TGF-β signaling are being pursued towards optimized therapeutic regimens for the treatment of mCRPC. In this review, we discuss the recent evidence on targeting the EMT-MET dynamic interconversions to overcome therapeutic resistance in patients with recurrent therapeutically resistant prostate cancer. Exploitation of the phenotypic landscape and metabolic changes that characterize the prostate tumor microenvironment in advanced prostate cancer and consequential impact in conferring treatment resistance are also considered in the context of biomarker discovery.
Insights
Therapeutic resistance in advanced prostate cancer is driven by the tumor microenvironment and epithelial-mesenchymal transition (EMT). Targeting EMT-MET dynamics offers a new strategy to overcome treatment resistance in metastatic castration-resistant prostate cancer (mCRPC).
Area of Science:
- Oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Advanced lethal prostate cancer often develops resistance to androgen-deprivation therapy (ADT) and chemotherapy.
- Therapeutic resistance is influenced by the tumor microenvironment, not solely androgen receptor (AR) signaling.
- Epithelial-mesenchymal transition (EMT), driven by transforming growth factor-β (TGF-β), promotes cancer cell survival, invasion, and stem cell properties via anoikis resistance.
Purpose of the Study:
- To review recent evidence on targeting the dynamic interconversions between EMT and mesenchymal-epithelial transition (MET) to overcome therapeutic resistance in prostate cancer.
- To explore the role of the tumor microenvironment and phenotypic plasticity in conferring treatment resistance.
- To identify potential new drug targets and therapeutic strategies for advanced, treatment-resistant prostate cancer.
Main Methods:
- Review of current scientific literature focusing on EMT, MET, anoikis, and the tumor microenvironment in prostate cancer.
- Analysis of signaling pathways involved in therapeutic resistance, including AR and TGF-β.
- Discussion of potential therapeutic interventions targeting EMT-MET dynamics and associated biomarkers.
Main Results:
- EMT facilitates resistance to anoikis, promoting metastasis and chemoresistance through mechanisms like E-cadherin loss.
- The plasticity of prostate tumor epithelium allows for EMT and MET, contributing to tumor progression and treatment resistance.
- The lead agent DZ-50 shows potential efficacy in metastatic castration-resistant prostate cancer (mCRPC) by inducing an anoikis-driven therapeutic response.
Conclusions:
- Targeting the EMT-MET dynamic is a promising strategy to overcome therapeutic resistance in advanced prostate cancer.
- Understanding the tumor microenvironment's role is crucial for developing effective treatments for resistant prostate cancer.
- Further research into targeting androgen/AR and TGF-β signaling interactions may optimize therapeutic regimens for mCRPC.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Therapeutic Index
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...

